抗病毒联合治疗有症状COVID-19感染患者的安全性和有效性——一项随机对照试验(SEV-COVID试验):随机对照试验研究方案的结构化摘要
该试验为开放标签、平行组、分层随机对照试验,纳入RT-PCR确诊且年龄≥18岁的有症状COVID-19患者,按预设标准分为非重症和重症两组。非重症组按1:1随机接受标准治疗或羟氯喹+利巴韦林+标准治疗;重症组按1:1:1随机接受标准治疗、羟氯喹+利巴韦林+标准治疗或洛匹那韦-利托那韦+利巴韦林+标准治疗。主要终点为临床恢复时间和SARS-CoV-2 RT-PCR转阴时间,随访28天。
要点
- 非重症COVID-19患者比较羟氯喹+利巴韦林联合标准治疗与单纯标准治疗。
- 重症患者三臂比较标准治疗、羟氯喹+利巴韦林及洛匹那韦-利托那韦+利巴韦林。
- 主要终点为临床恢复时间及上呼吸道SARS-CoV-2 RT-PCR转阴时间。
核心结论
- 该试验旨在评估羟氯喹联合利巴韦林及洛匹那韦-利托那韦联合利巴韦林在非重症和重症COVID-19患者中的安全性和有效性,结果尚未报告。
研究设计与样本
- 开放标签、平行组设计、分层随机对照试验,在三级医疗中心开展。
- 非重症组按1:1随机分配至两个治疗臂,重症组按1:1:1随机分配至三个治疗臂。
- 纳入标准:年龄≥18岁、RT-PCR确诊SARS-CoV-2感染、有症状的COVID-19、愿意接受随机分组。
- 排除标准包括使用禁忌药物、已接受抗逆转录病毒治疗、已知禁忌症、过敏、妊娠或哺乳、30天内接受过实验性治疗。
- 样本量:探索性试验,招募期内所有符合条件并同意者均纳入,招募期5个月(2020年6月至10月)。
关键数值与推荐
- 非重症组羟氯喹用法:首日400 mg每日两次,随后400 mg每日一次口服共10天;利巴韦林负荷剂量1.2 g口服,随后600 mg口服每12小时一次,共10天。
- 重症组羟氯喹用法:首日400 mg每日两次,随后400 mg每日一次;利巴韦林用法同非重症组;洛匹那韦200 mg+利托那韦50 mg两片每日两次,联合利巴韦林同前,共10天。
- 主要终点:临床恢复时间(从治疗开始至发热、呼吸频率、氧饱和度正常化及咳嗽缓解并持续至少72小时的时间,小时)和上呼吸道SARS-CoV-2 RT-PCR转阴时间。
- 次要终点包括全因死亡率、呼吸进展频率(室内空气下SPO2≤94%或PaO2/FiO2<300 mmHg且需 supplemental oxygen 或更高级通气支持)、退热时间、需 supplemental oxygen 或无创通气频率、需机械通气频率、严重不良事件频率(按DAIDS分级)。
- 随访28天或至出院或死亡(以较长者为准)。
局限性
- 开放标签设计,研究者和参与者均知晓治疗分配。
- 探索性试验,样本量未基于效力计算,所有符合条件者均纳入。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: 1. To compare the safety and efficacy of Hydroxychloroquine with Ribavirin and standard treatment in patients with non-severe COVID-19 infection 2. To compare the safety and efficacy of standard treatment, Lopinavir-ritonavir with Ribavarin, and Hydroxychloroquine with Ribavirin in patients with severe COVID-19 infection TRIAL DESIGN: The study is an Open label, Parallel arm design, stratified randomised controlled trial. Patients will be categorised as non-severe or severe based on predefined criteria. Those who satisfy all inclusion criteria and no exclusion criteria in the respective categories, will be randomly assigned to one of the three treatment groups in a ratio of 1:1 in the non-severe category and 1:1:1 in the severe category. PARTICIPANTS: The trial will be undertaken in a tertiary care center of the country where both Covid and non-Covid patients are getting treated. All patients who are confirmed positive and admitted will be screened for the eligibility criteria and will be enrolled in the study after a written informed consent. Patients will be categorised as non-severe or severe based on predefined criteria. INCLUSION CRITERIA (ALL REQUIRED): 1. Age ≥18 years at time of participation in the study 2. Laboratory (RT-PCR) confirmed infection with SARS-CoV-2 3. Symptomatic (severe or non-severe) Covid-19 disease 4. Willingness of study participant to accept randomization to any assigned treatment arm EXCLUSION CRITERIA: 1. Use of medications that are contraindicated with Lopinavir/Ritonavir, Hydroxychloroquine/Chloroquine, or Ribavirin and that cannot be replaced or stopped 2. Patient already on antiretroviral therapy with Lopinavir-Ritonavir based regimen or on Hydroxychloroquine/Chloroquine or on Ribavirin 3. Any known contraindication to test drugs such as retinopathy and QT prolongation 4. Known allergic reaction or inability to take orally of Lopinavir-ritonavir, Hydroxychloroquine/ Chloroquine, Ribavarin 5. Pregnant or breastfeeding females 6. Receipt of any experimental treatment for 2019-nCoV (off-label, compassionate use, or trial related) within 30 days prior to participation in the present study or want to participate after enrolment INTERVENTION AND COMPARATOR: Two therapeutic interventions for non-severe category and three for severe category as described below NON-SEVERE TREATMENT ARMS (NS-GROUP): Treatment Arm Drug A Standard Treatment (STNS) B Hydroxychloroquine 400 mg twice on first day followed by 400 mg per oral daily for 10 days + Ribavirin (1.2 g orally as a loading dose followed by 600mg orally every 12 hours) for 10 days + Standard Treatment (STNS) Standard Treatment for non-severe cases (STNS): Strict Isolation, Standard Precautions (Hand hygiene, Cough Etiquette, Wear surgical mask), Hydration, Proper Nutrition, Supportive Pharmacotherapy (Antipyretic, Antiallergic, Cough Suppressant), Treatment of Comorbid Diseases, Oseltamivir (75 mg BD) for patients who are tested positive for H1N1. SEVERE GROUP TREATMENT ARMS (S-GROUP): Treatment Arm Drug A Standard Treatment (STs) B Hydroxychloroquine 400mg BD on day1 followed by 400 mg once daily + Ribavirin (1.2 g orally as a loading dose followed by 600mg orally every 12 hours) for 10 days + Standard Treatment (STs) C Lopinavir(200mg) + Ritonavir (50mg) two tablets twice daily+ Ribavirin (1.2g orally as a loading dose followed by 600mg orally every 12 hours) for 10 days + Standard Treatment (STs)6 Standard Treatment for severe patients (STs): Strict Isolation, Standard Precautions (Hand hygiene, Cough Etiquette, Wear surgical mask), Fluid Therapy, Supportive Pharmacotherapy (Antipyretic, Antiallergic, Cough Suppressant), Oxygen supplementation (As required), Invasive ventilation (As required), Antibiotic agents for other associated infections (according to 2019 ATS/IDSA guidelines for non-ICU and ICU patients), Vasopressor support, Renal-replacement therapy, Treatment of Comorbid Diseases, Oseltamivir (75 mg BD) for patients who are tested positive for H1N1. MAIN OUTCOMES: Primary endpoints: (1) Time to Clinical recovery (TTCR) defined as the time (in hours) from initiation of study treatment (active or placebo) until normalisation of fever, respiratory rate, oxygen saturation, and alleviation of cough, sustained for at least 72 hours. (2) Time to SARS-CoV-2 RT-PCR negative in upper respiratory tract specimen, time to laboratory recovery of each organ involvement. Secondary Endpoints: All causes mortality, Frequency of respiratory progression (defined as SPO2≤ 94% on room air or PaO2/FiO2 <300mmHg and requirement for supplemental oxygen or more advanced ventilator support), time to defervescence (in those with fever at enrolment), frequency of requirement for supplemental oxygen or non-invasive ventilation, frequency of requirement for mechanical ventilation, frequency of serious adverse events as per DAIDS table grade of severity. Outcomes are monitored for 28 days from the time of enrolment into the study OR until the patient is discharged or death whichever is longer. RANDOMIZATION: The randomization will be done using a secured central computer-based randomization using a secure website using a central, computer-based randomisation program in a ratio of 1:1 in the non-severe category and 1:1:1 in the severe category. BLINDING (MASKING): This is an open labelled study i.e. Study assigned treatment will be known to the research team, the investigators and participants. NUMBERS TO BE RANDOMISED (SAMPLE SIZE): Since it is an exploratory trial as COVID-19 being a new disease, all patients who came under the purview of the inclusion criteria within the study period (5 months duration of the recruitment period of the total 6 months duration of the study i.e. from the month of June, 2020 to October 2020) and who have consented for the study will be included. TRIAL STATUS: Protocol version:1.0 Recruitment start: June 3rd, 2020 (Ongoing) Recruitment finish (expected): October 31st, 2020 TRIAL REGISTRATION: Clinical Trial Registry of India (CTRI): CTRI/2020/06/025575 . Registration on 03 June 2020 FULL PROTOCOL: The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this letter serves as a summary of the key elements of the full protocol.
引用
- Panda PK, Bandyopadhyay A, Singh BC, et al. Safety and efficacy of antiviral combination therapy in symptomatic patients of Covid-19 infection - a randomised controlled trial (SEV-COVID Trial): A structured summary of a study protocol for a randomized controlled trial. Trials. 2020. PMID: 33081849. doi:10.1186/s13063-020-04774-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。